• OPEN AN ACCOUNT
Indian Indices
Nifty
25,910.05 -103.40
(-0.40%)
Sensex
84,673.02 -277.93
( -0.33%)
Bank Nifty
58,899.25 -63.45
( -0.11%)
Nifty IT
35,975.20 -400.00
( -1.10%)
Global Indices
Nasdaq
46,604.53 -563.95
(-1.20%)
Dow Jones
6,692.71 -62.40
(-0.92%)
Hang Seng
48,833.62 -1,490.29
(-2.96%)
Nikkei 225
9,519.69 -155.74
(-1.61%)
Forex
USD-INR
88.65 -0.06
(-0.07%)
EUR-INR
103.02 -0.02
(-0.02%)
GBP-INR
116.73 0.00
(0.00%)
JPY-INR
0.57 0.00
(-0.02%)

EQUITY - MARKET SCREENER

Sun Pharmaceutical Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
99.2482659
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
90.54
423170.71
EPS(TTM)
Face Value()
Div & Yield %
19.48
1
0.91
 

sun pharmaceuticals industries ltd
Astrazeneca Pharma and Sun Pharma form second brand partnership
Nov 17,2025
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.